2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Immune Mechanism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Viral, Bacterial, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2711 First-line polatuzumab-containing regimens in older patients with newly diagnosed DLBCL: Clinical outcomes, safety, and longitudinal patient-reported outcomes from a real-world study

Zhao Peiqi, MD, Shiyong Zhou2, Zhengzi Qian3, Lanfang Li4, Zheng Song, PhD5, Lihua Qiu6, Huilai Zhang, PhD7
1 Department of Lymphoma, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China
2 Department of Lymphoma, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China
3 Department of Lymphoma, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China
4 Department of Lymphoma, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China
5 Department of Lymphoma, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China
6 Department of Lymphoma, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China
7 Department of Lymphoma, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China

Background
Older adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) are vulnerable to treatment-related toxicity and functional decline. Although polatuzumab vedotin–based first-line therapy has improved outcomes in clinical trials, real-world evidence integrating clinical effectiveness, safety, and longitudinal patient-reported outcomes (PROs) in this population remains limited.
Methods
This is a prospective, noninterventional, single-cohort real-world study of older adults with newly diagnosed DLBCL treated with first-line polatuzumab-containing regimens. End-of-treatment (EOT) responses were summarized among EOT-evaluable patients, with two-sided Wilson 95% confidence intervals (CIs) for the objective response rate (ORR) and complete response (CR) rate. Adverse events (AEs) were summarized at the patient level using the highest recorded grade. PROs were assessed using the EORTC QLQ-C30, QLQ-CIPN20, Instrumental Activities of Daily Living (IADL), and EQ-5D-5L across chronologically ordered Assessments 1–6. Core PRO domains were global health status (GHS)/quality of life (QoL), physical functioning, fatigue, and sensory symptoms. Within endpoint-specific paired cohorts, changes from Assessment 1 to Assessment 6 were summarized as mean paired changes with percentile 95% CIs from 10,000 patient-level bootstrap samples. At Assessment 6, clinically meaningful improvement, stability, or worsening was classified using prespecified thresholds. No multiplicity adjustment or missing-data imputation was performed.
Results
Forty-three patients were included. Median age was 73 years (IQR, 71–76; range, 69–89), 24 (55.8%) were female, 21 (48.8%) had an Eastern Cooperative Oncology Group performance status of 2–3, 32 (74.4%) had stage III/IV disease, 26 (60.5%) had an International Prognostic Index score of 4–5, and 28 (65.1%) had non-germinal-center B-cell–like DLBCL. All patients received a first-line polatuzumab-containing regimen for a median of 5 cycles (IQR, 4–6; range, 2–8). EOT response was evaluable in 39/43 patients (90.7%). Among EOT-evaluable patients, the ORR was 94.9% (37/39; 95% CI, 83.1–98.6), including 28 CRs (71.8%; 95% CI, 56.2–83.5) and 9 partial responses (23.1%); 2 patients (5.1%) had progressive disease. Thirty-eight patients (88.4%) had at least 1 recorded AE. All recorded AEs were grade 1–2 and were predominantly hematologic: anemia (65.1%), decreased neutrophil count (18.6%), and decreased white blood cell count (16.3%). No grade ≥3 AEs, serious AEs, or AE-related hospitalizations were recorded. Overall, 41 patients contributed 218 PRO assessments. Across Assessments 2–6, mean GHS/QoL and physical functioning fluctuated around Assessment 1 values, with no progressive worsening of sensory symptoms. At Assessment 6 (paired n=15–18), mean changes from Assessment 1 were +2.31 points for GHS/QoL (95% CI, −8.80 to 13.43), −1.27 for physical functioning (95% CI, −14.51 to 12.16), −14.07 for fatigue (95% CI, −27.78 to −0.37; lower scores indicate improvement), and −3.42 for sensory symptoms (95% CI, −13.83 to 4.39; lower scores indicate fewer symptoms). Clinically meaningful improvement or stability at Assessment 6 was observed in 72.2% of patients for GHS/QoL, 64.7% for physical functioning, and 66.7% for fatigue; 60.0% achieved a clinically meaningful reduction in fatigue. At data cutoff, 4 progression-free survival events and 2 deaths had been recorded; time-to-event estimates were not calculated because follow-up remained immature and event dates were incomplete.
Conclusions
In this prospective real-world cohort of older patients with newly diagnosed DLBCL, first-line polatuzumab-containing regimens were associated with high EOT response rates and predominantly low-grade hematologic toxicity. Longitudinal PROs showed no consistent deterioration in overall health status, physical functioning, or sensory symptoms, while fatigue improved meaningfully in a subset of patients. These findings are descriptive and should be interpreted in the context of the single-cohort design, small paired PRO samples, missing assessments, and immature survival follow-up.

Zhao Peiqi, MD: No relevant conflicts of interest to declare.